{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:49:55Z","timestamp":1791272995969,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103448","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T10:43:13Z","timestamp":1638614593000},"page":"103448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis"],"prefix":"10.1016","volume":"57","author":[{"given":"David","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angray S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103448_bib0006","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103448_bib0027","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2021.103448_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2021.103448_bib0015","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103448_bib0016","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103448_bib0001","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44a","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103448_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2021.103448_bib0022","article-title":"Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?","author":"Baker","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2021.103448_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3599","article-title":"Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab","author":"Brill","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103448_bib0030","article-title":"Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series","author":"Connolly","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103448_bib0024","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103448_bib0013","article-title":"Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to SARS-CoV-2 vaccines in patients with multiple sclerosis","volume":"23","author":"Disanto","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103448_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2021.103448_bib0014","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2021.103448_bib0031","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.msard.2021.103448_bib0035","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/v13040628","article-title":"Neutralizing antibody therapeutics for COVID-19","volume":"13","author":"Hurt","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2021.103448_bib0002","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.msard.2021.103448_bib0033","article-title":"Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders","author":"K\u00f6nig","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.msard.2021.103448_bib0023","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"issue":"Suppl 15","key":"10.1016\/j.msard.2021.103448_bib0017","article-title":"Pharmacokinetics, pharmacodynamics and exposure-response analyses of ocrelizumab in patients with multiple sclerosis (N4.001)","volume":"92","author":"Kletzl","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103448_bib0036","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/antibiotics10111294","article-title":"Molnupiravir-a novel oral anti-SARS-CoV-2 Agent","volume":"10","author":"Lee","year":"2021","journal-title":"Antibiotic"},{"key":"10.1016\/j.msard.2021.103448_bib0004","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103448_bib0019","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103448_bib0010","first-page":"ciab954","article-title":"Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines","author":"Madelon","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2021.103448_bib0011","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: b cells promote humoral immune responses in the presence of T-cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2021.103448_bib0032","article-title":"Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies","author":"Re","year":"2021","journal-title":"Medrxiv"},{"key":"10.1016\/j.msard.2021.103448_bib0020","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.103448_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103448_bib0034","article-title":"Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0)","author":"Sidler","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.msard.2021.103448_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102186","article-title":"BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab","volume":"43","author":"Signoriello","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103448_bib0005","article-title":"SARS-CoV-2 serology after COVID-19 in multiple sclerosis: an international cohort study","volume":"30","author":"Sormani","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103448_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2021.103448_bib0012","article-title":"B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab","author":"Stefanski","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.msard.2021.103448_bib0008","article-title":"COVID-19 vaccine response in people with multiple sclerosis","author":"Tallantyre","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103448_bib0026","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2114706","article-title":"Genotype to phenotype Japan (g2p-japan) consortium. neutralization of the SARS-CoV-2 mu variant by convalescent and vaccine serum","author":"Uriu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103448_bib0021","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","author":"van Lierop","year":"2021","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821007148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821007148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:37:22Z","timestamp":1735558642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821007148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"alternative-id":["S2211034821007148"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103448","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.26.21264023","asserted-by":"object"}]},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103448"}}